Lyles, D.S. (2000). Cytopathogenesis and inhibition of host gene expression by RN A viruses. Microbiol. Mol. Biol. Rev. 64, 709-724.
Lyles, D.S., McKenzie, M.O., Kaptur, P.E., Grant, K.W., and Jerome, W.G. (1996). Complementation of M gene mutants of Vesicular Stomatitis Virus by plasmid-derived M protein convert$ spherical extracellular particles into native bullet shapes. Virology 2/7, 76-87.
Lyles, D.S., Puddington, L., and McCreedy, B.J.J. (1988). Vesicular stomatitis virus M protein in the nuclei of infected cells. Journal of virolgy (52,4387-4392.
Macor, P., and Tedesco, F. (2007). Complement as effector system in cancer immunotherapy. Immunol. Lett. ///, 6-13.
Mader, E., Butler, G., Dowdy, S., Mariani, A., Knutson, K., Federspiel, M., Russell, S., Galanis, E., Dietz, A., and Peng, K.-W. (2013). Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer. Journal of Translational Medicine //, 20.
Magge, D., Guo, Z., 0'MaIley, M., Francis, L., Ravindranathan, R., and Bartlett, D (2013). Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Ther. 20, 342-350.
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Naturę 454,436-444.
Mantwill, K., Kohler-Vargas, N., Bemshausen, A., Bieler, A., Lagę, H., Kaszubiak, A., Surowiak, P., Dravits, T., Treiber, U., Hartung, R.t et al. (2006). Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: Implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res. 66, 7195-7202.
Marigo, I., Dolcetti, L., SeraFuii, P., Zanovello, P., and Bronte, V. (2008). Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev 222, 162-179.
Markert, J.M., Medlock, M.D., Rabkin, S.D., Gillespie, G.Y., Todo, T., Hunter, W.D., Palmer, C.A., Feigenbaum, F., Tomatore, C., Tufaro, F., and Martuza, R.L. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7.
203